Skip to content

Corticosteroid effectiveness in treating severe community acquired pneumonia

Efficacy of Corticosteroid Therapy in Severe Community Acquired Pneumonia

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/12/048583
Enrollment
50
Registered
2022-12-29
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J189- Pneumonia, unspecified organism

Interventions

Intervention1: INJECTION METHYLPREDNISOLONE 0.5 MG/KG EVERY 12 HOURS FOR 5 DAYS: Patients belonging to the intervention group, after giving proper consent and fulfilling the inclusion criteria will be

Sponsors

GOVERNMENT MEDICAL COLLEGE AND HOSPITAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age more than 18year. 2. Patients have clinical symptoms suggesting community acquired pneumonia (cough, fever, pleuritic chest pain and/or shortness of breath) 3. Patient who will be diagnosed as a case of severe community acquired pneumonia as per the criteria ATS IDSA 2007 4. Those who will give consent for study.

Exclusion criteria

Exclusion criteria: 1. Immunocompromised patients i.e. HIV infection, neutropenic patients(1000Ã?109 /L), stem cell transplant recipients, patients on immunosuppressive treatment other than corticosteroid, patients of leukemia/lymphoma, chronic liver disease, chronic kidney disease, coronary artery disease and/ or chronic heart failure. 2. Clinical suspicion of Tuberculosis 3. Gastrointestinal bleeding in past three months 4. Conditions requiring adjunctive long-term corticosteroid therapy (with an equivalent dose of Inj methylprednisolone 1mg/kg/d or more) 5. Patients with pneumonia secondary to aspiration, hospital-acquired infection, prior treatment in ICU or receipt of mechanical ventilation. 6. Evidence of empyema, cavitary lung lesion or lung abscess as a complication.

Design outcomes

Primary

MeasureTime frame
Reduction in the rates of treatment failure (early, late and/or both)Timepoint: day 0, 3, 6

Secondary

MeasureTime frame
Attainment of clinical stabilityTimepoint: day 0, 3, 6;Effect of corticosteroid therapy on length of stay in hospital.Timepoint: day 0, 3, 6;Mortality during index hospitalization and at 28 days post discharge.Timepoint: day 0, 3, 6, 28

Countries

India

Contacts

Public ContactDR ANURAG DAHRA

Government Medical College and Hospital Sector 32, Chandigarh

pritam_doc@yahoo.com9646121560

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026